Skip to main content

Douglas Johnson Archives

Directorships honor VUMC leaders and philanthropic partners

Dec. 2, 2021—Ten Vanderbilt University Medical Center leaders from across the enterprise in clinical care, research, education and administration have been named as holders of endowed directorships.

Read more


Seven from VUMC among most highly cited researchers

Nov. 18, 2021—Seven Vanderbilt faculty members have made this year’s list of scientists whose papers have been cited most frequently by other researchers.

Read more


Forty-three percent of melanoma patients have chronic complications from immunotherapies

Mar. 25, 2021—Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.

Read more


Study identifies targeted therapy’s cardiac risks

Sep. 25, 2019—After a recent study showed that chronic lymphocytic leukemia patients who received ibrutinib as a frontline treatment had a 7% death rate, a new study offers a clearer picture on the reasons for the deaths.

Read more


Encephalitis identified as rare toxicity of immunotherapy treatment

Jul. 22, 2019—Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.

Read more


Medical Societies honor multiple Vanderbilt faculty

Apr. 18, 2019—Several Vanderbilt faculty members were recently honored during the joint annual meeting of the Association of American Physicians (AAP) and American Society for Clinical Investigation (ASCI).

Read more


Immunotherapies linked to specific heart complications

Nov. 15, 2018—In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have shown that heart and vessel complications include myocarditis, pericarditis, vasculitis and arrhythmias, and that they occur early in the course of treatment.

Read more


Study tracks incidence, timing of immunotherapy-related deaths

Sep. 13, 2018—Vanderbilt-Ingram Cancer Center researchers have answered questions about the incidence and timing of rare but sometimes fatal reactions to the most widely prescribed class of immunotherapies.

Read more


Entertainers’ support strengthens VICC melanoma research efforts

Apr. 12, 2018—Henry Paul and Dave Robbins, members of country music group BlackHawk, as well as southern rock band The Outlaws, recently donated $40,000 to Vanderbilt-Ingram Cancer Center (VICC) in support of melanoma research. Since 2006, the band members have generated more than $100,000 for VICC.

Read more


Cancer immunotherapy drugs linked with more serious heart effects

Mar. 12, 2018—Vanderbilt University Medical Center investigators have identified a growing number of serious and sometimes fatal cases of heart problems among cancer patients treated with some forms of immunotherapy.

Read more


Study details rare heart risk of certain cancer therapies

Nov. 3, 2016—Combination therapy using two approved immunotherapy drugs for cancer treatment may cause rare and sometimes fatal cardiac side effects linked to an unexpected immune response. In a study led by Vanderbilt University Medical Center (VUMC) investigators and published in the Nov. 3 issue of the New England Journal of Medicine, researchers describe two cases of...

Read more


Precision medicine already changing cancer treatment strategies

May. 26, 2016—The ability to test patients’ cancers for individual differences, mainly at the genetic level, and to make treatment decisions based on those differences is the hallmark of precision medicine, and Vanderbilt University Medical Center (VUMC) is among the leaders of this new approach to diagnosis and treatment.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more